Home

Our Technology

Innovative Chemistry
Transformative Therapies

FDA “Fast Track” and “Breakthrough Therapy” designations received. 

About us

What We Do

We’re a biotech company committed to stemming the prescription drug abuse epidemic.

Investment

Long Term
Opportunity

Events & Presentations

Ensysce Corporate Overview Find Out More
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program Read More
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting Read More
Ensysce Biosciences Regains Compliance with Nasdaq Read More
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform Read More
Ensysce Biosciences Reports First Quarter 2024 Financial Results Read More
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine Read More

Our Team

Brilliant minds
and vision

We’re proud to say our team is made up of just that — people and minds both driven by passion and full of potential. Our company is led by a team of executives and directors with vast experience and proven track records in pain, drug development and commercialization.

D. Lynn Kirkpatrick, PhD

Chief Executive Officer

Dave Humphrey

Chief Financial Officer

Bill Schmidt, PhD

Chief Medical Officer.

Jeffrey Millard, PhD

Chief Operating Officer

Geoff Birkett

Chief Commercial Officer

Linda Pestano, PhD

Chief Development Officer